Artículos por temáticas

Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer's disease

Cummings JL, Zhong K, Kinney JW, Heaney C, Moll-Tudla J, Joshi A, Pontecorvo M, Devous M, Tang A, Bena J.

Alzheimers Res Ther. 2016 Jan 29;8:4. doi: 10.1186/s13195-016-0173-2.

Gamma Secretase Modulators: New Alzheimer's Drugs on the Horizon?

Bursavich MG, Harrison BA, Blain JF.

J Med Chem. 2016 Aug 25;59(16):7389-409. doi: 10.1021/acs.jmedchem.5b01960. Epub 2016 Apr 5.

Neuroprotective Effects of Fisetin in Alzheimer's and Parkinson's Diseases: From Chemistry to Medicine

Nabavi SF, Braidy N, Habtemariam S, Sureda A, Manayi A, Nabavi SM.

Curr Top Med Chem. 2016;16(17):1910-5. doi: 10.2174/1568026616666160204121725.

Combination Therapy Showed Limited Superiority Over Monotherapy for Alzheimer Disease: A Meta-analysis of 14 Randomized Trials

Tsoi KK, Chan JY, Leung NW, Hirai HW, Wong SY, Kwok TC.

J Am Med Dir Assoc. 2016 Sep 1;17(9):863.e1-8. doi: 10.1016/j.jamda.2016.05.015. Epub 2016 Jun 24.

Designing Multi-Targeted Therapeutics for the Treatment of Alzheimer's Disease

Orhan IE, Senol FS.

Curr Top Med Chem. 2016;16(17):1889-96. doi: 10.2174/1568026616666160204121832.

Disclosure of positron emission tomography amyloid imaging results: A preliminary study of safety and tolerability

Lim YY, Maruff P, Getter C, Snyder PJ.

Alzheimers Dement. 2016 Apr;12(4):454-8. doi: 10.1016/j.jalz.2015.09.005. Epub 2015 Dec 30.

The effect of memantine on sleep architecture and psychiatric symptoms in patients with Alzheimer's disease

Ishikawa I, Shinno H, Ando N, Mori T, Nakamura Y.

Acta Neuropsychiatr. 2016 Jun;28(3):157-64. doi: 10.1017/neu.2015.61. Epub 2015 Nov 17.

Benefits of use, and tolerance of, medium-chain triglyceride medical food in the management of Japanese patients with Alzheimer's disease: a prospective, open-label pilot study

Ohnuma T, Toda A, Kimoto A, Takebayashi Y, Higashiyama R, Tagata Y, Ito M, Ota T, Shibata N, Arai H.

Clin Interv Aging. 2016 Jan 8;11:29-36. doi: 10.2147/CIA.S95362. eCollection 2016.

First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer's disease

Delnomdedieu M, Duvvuri S, Li DJ, Atassi N, Lu M, Brashear HR, Liu E, Ness S, Kupiec JW.

Alzheimers Res Ther. 2016 Mar 1;8(1):12. doi: 10.1186/s13195-016-0177-y.

Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial

Gauthier S, Feldman HH, Schneider LS, Wilcock GK, Frisoni GB, Hardlund JH, Moebius HJ, Bentham P, Kook KA, Wischik DJ, Schelter BO, Davis CS, Staff RT, Bracoud L, Shamsi K, Storey JM, Harrington CR, W

Lancet. 2016 Dec 10;388(10062):2873-2884. doi: 10.1016/S0140-6736(16)31275-2. Epub 2016 Nov 16.

A comparative evaluation of treatments with 17β-estradiol and its brain-selective prodrug in a double-transgenic mouse model of Alzheimer's disease

Tschiffely AE, Schuh RA, Prokai-Tatrai K, Prokai L, Ottinger MA.

Horm Behav. 2016 Jul;83:39-44. doi: 10.1016/j.yhbeh.2016.05.009. Epub 2016 May 19.

Can angiotensin-converting enzyme inhibitors impact cognitive decline in early stages of Alzheimer's disease? An overview of research evidence in the elderly patient population

Rygiel K.

J Postgrad Med. 2016 Oct-Dec;62(4):242-248. doi: 10.4103/0022-3859.188553.

Inhibitory activities of major anthraquinones and other constituents from Cassia obtusifolia against β-secretase and cholinesterases

Jung HA, Ali MY, Jung HJ, Jeong HO, Chung HY, Choi JS.

J Ethnopharmacol. 2016 Sep 15;191:152-160. doi: 10.1016/j.jep.2016.06.037. Epub 2016 Jun 15.

Sedation mediates part of Citalopram's effect on agitation in Alzheimer's disease

Newell J, Yesavage JA, Taylor JL, Kraemer HC, Munro CA, Friedman L, Rosenberg PB, Madore M, Chao SZ, Devanand DP, Drye LT, Mintzer JE, Pollock BG, Porsteinsson AP, Schneider LS, Shade DM, Weintraub D,

J Psychiatr Res. 2016 Mar;74:17-21. doi: 10.1016/j.jpsychires.2015.12.005. Epub 2015 Dec 12.

Unlocking Electronic Medical Record Data to Identify Possible Connections Between Cancer and Cognitive Declines

McGinty HL.

J Clin Oncol. 2016 Feb 20;34(6):530-2. doi: 10.1200/JCO.2015.65.2248. Epub 2015 Dec 28.